

**Clinical trial results:****A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - Vericiguat GLOBAL Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)****Summary**

EudraCT number	2016-000671-25
Trial protocol	DE SE CZ HU ES FR GB DK NL FI PL BE GR AT IT
Global end of trial date	02 September 2019

Results information

Result version number	v1 (current)
This version publication date	12 September 2020
First version publication date	12 September 2020

Trial information**Trial identification**

Sponsor protocol code	1242-001
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02861534
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 September 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 June 2019
Global end of trial reached?	Yes
Global end of trial date	02 September 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 September 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 205
Country: Number of subjects enrolled	Australia: 48
Country: Number of subjects enrolled	Austria: 67
Country: Number of subjects enrolled	Belgium: 18
Country: Number of subjects enrolled	Canada: 145
Country: Number of subjects enrolled	Chile: 60
Country: Number of subjects enrolled	China: 315
Country: Number of subjects enrolled	Colombia: 224
Country: Number of subjects enrolled	Czech Republic: 110
Country: Number of subjects enrolled	Denmark: 53
Country: Number of subjects enrolled	Finland: 12
Country: Number of subjects enrolled	France: 76
Country: Number of subjects enrolled	Germany: 212
Country: Number of subjects enrolled	Greece: 70
Country: Number of subjects enrolled	Guatemala: 38
Country: Number of subjects enrolled	Hong Kong: 46
Country: Number of subjects enrolled	Hungary: 154
Country: Number of subjects enrolled	Ireland: 22

Country: Number of subjects enrolled	Israel: 218
Country: Number of subjects enrolled	Italy: 130
Country: Number of subjects enrolled	Japan: 319
Country: Number of subjects enrolled	Korea, Republic of: 83
Country: Number of subjects enrolled	Malaysia: 97
Country: Number of subjects enrolled	Mexico: 101
Country: Number of subjects enrolled	Netherlands: 42
Country: Number of subjects enrolled	New Zealand: 59
Country: Number of subjects enrolled	Norway: 22
Country: Number of subjects enrolled	Peru: 59
Country: Number of subjects enrolled	Philippines: 63
Country: Number of subjects enrolled	Poland: 302
Country: Number of subjects enrolled	Puerto Rico: 37
Country: Number of subjects enrolled	Russian Federation: 266
Country: Number of subjects enrolled	Singapore: 51
Country: Number of subjects enrolled	South Africa: 287
Country: Number of subjects enrolled	Spain: 116
Country: Number of subjects enrolled	Sweden: 62
Country: Number of subjects enrolled	Switzerland: 20
Country: Number of subjects enrolled	Taiwan: 102
Country: Number of subjects enrolled	Turkey: 196
Country: Number of subjects enrolled	Ukraine: 91
Country: Number of subjects enrolled	United Kingdom: 37
Country: Number of subjects enrolled	United States: 415
Worldwide total number of subjects	5050
EEA total number of subjects	1505

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1873
From 65 to 84 years	2894
85 years and over	283

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This trial enrolled participants with a history of chronic heart failure who were on standard therapy. Additional inclusion criteria applied.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Vericiguat

Arm description:

Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of heart failure (HF) standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg.

Arm type	Experimental
Investigational medicinal product name	Vericiguat
Investigational medicinal product code	
Other name	MK-1242
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2.5, 5.0, or 10.0 mg orally once daily

Arm title	Placebo
------------------	---------

Arm description:

Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo to vericiguat 2.5, 5.0, or 10.0 mg orally once daily

Number of subjects in period 1	Vericiguat	Placebo
Started	2526	2524
Treated	2519	2515
Completed	1952	1937
Not completed	574	587
Adverse event, serious fatal	541	552
Consent withdrawn by subject	15	18
Site Terminated by Sponsor	4	3
Lost to follow-up	14	14

Baseline characteristics

Reporting groups

Reporting group title	Vericiguat
-----------------------	------------

Reporting group description:

Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of heart failure (HF) standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg.

Reporting group values	Vericiguat	Placebo	Total
Number of subjects	2526	2524	5050
Age categorical			
Units: Subjects			

Age Continuous			
Units: Years			
arithmetic mean	67.5	67.2	
standard deviation	± 12.2	± 12.2	-
Sex: Female, Male			
Units: Participants			
Female	605	603	1208
Male	1921	1921	3842
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	24	28	52
Asian	571	561	1132
Native Hawaiian or Other Pacific Islander	3	11	14
Black or African American	123	126	249
White	1621	1618	3239
More than one race	183	180	363
Unknown or Not Reported	1	0	1

End points

End points reporting groups

Reporting group title	Vericiguat
Reporting group description: Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of heart failure (HF) standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg.	
Reporting group title	Placebo
Reporting group description: Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg.	

Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization

End point title	Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
End point description: Time to First Occurrence of Composite Endpoint of CV Death or HF Hospitalization was analyzed using a one-sided stratified log-rank test. Randomized participants without any HF hospitalization or CV death event at the time of analysis were censored at their last available information, the date of their non-CV death, or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A clinical events committee (CEC) reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years at risk) is provided. The analysis population for this end point included all randomized participants.	
End point type	Primary
End point timeframe: Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)	

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs at risk				
number (not applicable)	33.6	37.8		

Statistical analyses

Statistical analysis title	Time to First CV Death or HF Hospitalization
Comparison groups	Vericiguat v Placebo

Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.019
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	0.98

Secondary: Time to the First Occurrence of CV Death

End point title	Time to the First Occurrence of CV Death
End point description:	Time to First Occurrence of CV Death was analyzed using a one-sided stratified log-rank test. Randomized participants without a CV death at the time of analysis were censored at their last available information, the date of their non-CV death, or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A CEC reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years at risk) is provided. The analysis population for this end point included all randomized participants.
End point type	Secondary
End point timeframe:	Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs at risk				
number (not applicable)	12.9	13.9		

Statistical analyses

Statistical analysis title	Time to the First Occurrence of CV Death
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.269
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.06

Secondary: Time to the First Occurrence of HF Hospitalization

End point title	Time to the First Occurrence of HF Hospitalization
-----------------	--

End point description:

Time to the First Occurrence of HF Hospitalization was analyzed using a one-sided stratified log-rank test. Randomized participants without any HF hospitalization at the time of analysis were censored at their last available information, the date of their death, or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A CEC reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years at risk) is provided. The analysis population for this end point included all randomized participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs at risk				
number (not applicable)	25.9	29.1		

Statistical analyses

Statistical analysis title	Time to the First Occurrence of HF Hospitalization
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.048
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1

Secondary: Time to Total HF Hospitalizations (including first and recurrent events)

End point title	Time to Total HF Hospitalizations (including first and recurrent events)
-----------------	--

End point description:

Time to Total HF Hospitalizations (including first and recurring) was analyzed using an Andersen-Gill model. Randomized participants without any HF hospitalization at the time of analysis were censored at their last available information, the date of their death, or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A CEC reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years of follow-up) is provided. The analysis population for this end point included all randomized participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs				
number (not applicable)	38.3	42.4		

Statistical analyses

Statistical analysis title	Time to Total HF Hospitalizations
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.023
Method	Andersen-Gill model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	0.99

Secondary: Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization

End point title	Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization
-----------------	---

End point description:

Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization was analyzed using a one-sided stratified log-rank test. Randomized participants without any all-cause mortality event or HF hospitalization at the time of analysis were censored at their last available information or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A CEC reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years at risk) is provided. The analysis population for this end point included all randomized participants.

End point type	Secondary
End point timeframe:	
Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)	

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs at risk				
number (not applicable)	35.9	40.1		

Statistical analyses

Statistical analysis title	Time to All-Cause Mortality or HF Hospitalization
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.021
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	0.98

Secondary: Time to All-Cause Mortality

End point title	Time to All-Cause Mortality
-----------------	-----------------------------

End point description:

Time to All-Cause Mortality was analyzed using a one-sided stratified log-rank test. Randomized participants without any all-cause mortality event at the time of analysis were censored at their last available information or the primary analysis database cutoff date of 18-June-2019, whichever occurred first. A CEC reviewed and adjudicated the endpoint events. A time-to-event methodology was used to evaluate the results; the incidence rate of participants with an event (number of participants with an event per 100 participant-years at risk) is provided. The analysis population for this end point included all randomized participants.

End point type	Secondary
End point timeframe:	
Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)	

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2526	2524		
Units: Parts w/ event per 100 part-yrs at risk				
number (not applicable)	16.0	16.9		

Statistical analyses

Statistical analysis title	Time to All-Cause Mortality
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5050
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.377
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.07

Secondary: Number of Participants Who Experienced One or More Adverse Events

End point title	Number of Participants Who Experienced One or More Adverse Events
End point description:	
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The analysis population for this end point included all randomized participants who received at least 1 dose of study treatment.	
End point type	Secondary
End point timeframe:	
Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)	

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2519	2515		
Units: Participants	2027	2036		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Discontinued Treatment Due to an Adverse Event

End point title	Number of Participants Who Discontinued Treatment Due to an Adverse Event
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The analysis population for this end point included all randomized participants who received at least 1 dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2519	2515		
Units: Participants	167	158		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Experienced Symptomatic Hypotension

End point title	Percentage of Participants Who Experienced Symptomatic Hypotension
-----------------	--

End point description:

Study participants were monitored for symptomatic hypotension, an event of clinical interest, and results were reported. The analysis population for this end point included all randomized participants who received at least 1 dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2519	2515		
Units: Percentage of participants				
number (not applicable)	9.1	7.9		

Statistical analyses

Statistical analysis title	Pct of Parts Who Experienced Sympt Hypotension
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5034
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.121
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	2.8

Secondary: Percentage of Participants Who Experienced Syncope

End point title	Percentage of Participants Who Experienced Syncope
End point description:	Study participants were monitored for syncope, an event of clinical interest, and results were reported. The analysis population for this end point included all randomized participants who received at least 1 dose of study treatment.
End point type	Secondary
End point timeframe:	Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

End point values	Vericiguat	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2519	2515		
Units: Percentage of participants				
number (not applicable)	4.0	3.5		

Statistical analyses

Statistical analysis title	Pct of Participants Who Experienced Syncope
Comparison groups	Vericiguat v Placebo
Number of subjects included in analysis	5034
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.303
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	1.6

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to approximately 35 months (through Last Participant Last Visit date of 02-Sept-2019)

Adverse event reporting additional description:

Serious Adverse Events and Non-Serious Adverse Events: All randomized participants who received at least 1 dose of study treatment.

Number of Deaths (all causes): All randomized participants (n=2526, n=2524).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.0

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg.

Reporting group title	Vericiguat
-----------------------	------------

Reporting group description:

Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg.

Serious adverse events	Placebo	Vericiguat	
Total subjects affected by serious adverse events			
subjects affected / exposed	897 / 2515 (35.67%)	852 / 2519 (33.82%)	
number of deaths (all causes)	561	553	
number of deaths resulting from adverse events	1	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	1 / 2515 (0.04%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal gland cancer metastatic			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiocentric lymphoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastric neoplasm			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			

subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	4 / 2515 (0.16%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic lymphocytic leukaemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon neoplasm			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cutaneous T-cell lymphoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric cancer			
subjects affected / exposed	1 / 2515 (0.04%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma multiforme			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cancer			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic neoplasm			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatobiliary cancer			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular carcinoma			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammatory pseudotumour			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung neoplasm malignant			
subjects affected / exposed	4 / 2515 (0.16%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Lymphoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoproliferative disorder			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			

subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to abdominal cavity			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lung			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic neoplasm			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myelodysplastic syndrome			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal cancer			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma metastatic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Plasma cell myeloma			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Plasmacytoma			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Polycythaemia vera			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	5 / 2515 (0.20%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	0 / 2515 (0.00%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal cancer			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sweat gland tumour			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
T-cell lymphoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Tongue neoplasm malignant stage unspecified			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour ulceration			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Uterine cancer			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arterial occlusive disease			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding varicose vein			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic vasculitis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	4 / 2515 (0.16%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	5 / 2515 (0.20%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	44 / 2515 (1.75%)	33 / 2519 (1.31%)	
occurrences causally related to treatment / all	10 / 45	9 / 34	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypovolaemic shock			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery occlusion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphorrhoea			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 2515 (0.04%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	1 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	11 / 2515 (0.44%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 12	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	3 / 2515 (0.12%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral vascular disorder			

subjects affected / exposed	3 / 2515 (0.12%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Shock haemorrhagic			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein ruptured			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular occlusion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Aortic aneurysm repair			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia prophylaxis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker replacement			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac rehabilitation therapy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac resynchronisation therapy			
subjects affected / exposed	7 / 2515 (0.28%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular event prophylaxis			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardioversion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central venous catheter removal			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator insertion			
subjects affected / exposed	2 / 2515 (0.08%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator removal			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator replacement			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular lens implant			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephroprotective therapy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Therapeutic procedure			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe operation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 2515 (0.24%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac complication associated with device			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	8 / 2515 (0.32%)	10 / 2519 (0.40%)	
occurrences causally related to treatment / all	0 / 14	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related thrombosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Discomfort			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			

subjects affected / exposed	1 / 2515 (0.04%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site erythema			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site haematoma			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza like illness			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device pain			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site haematoma			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site swelling			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site thrombosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	4 / 2515 (0.16%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	7 / 2515 (0.28%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Physical deconditioning			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sensation of foreign body			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated hernia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
UGT1A1 gene polymorphism			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent thrombosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Amyloidosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	8 / 2515 (0.32%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	7 / 2515 (0.28%)	9 / 2519 (0.36%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 2	
Asthma			
subjects affected / exposed	4 / 2515 (0.16%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	30 / 2515 (1.19%)	38 / 2519 (1.51%)	
occurrences causally related to treatment / all	0 / 50	0 / 51	
deaths causally related to treatment / all	0 / 0	0 / 3	
Chylothorax			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	7 / 2515 (0.28%)	11 / 2519 (0.44%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			

subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperventilation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			

subjects affected / exposed	13 / 2515 (0.52%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 15	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pleurisy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	2 / 2515 (0.08%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	4 / 2515 (0.16%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	6 / 2515 (0.24%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Pulmonary haematoma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary infarction			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	3 / 2515 (0.12%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	5 / 2515 (0.20%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinitis hypertrophic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillar haemorrhage			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Alcohol abuse			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety disorder			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Delirium			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug use disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device battery issue			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device ineffective			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lead dislodgement			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biloma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	4 / 2515 (0.16%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	6 / 2515 (0.24%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholecystitis chronic			

subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatic failure			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic congestion			
subjects affected / exposed	0 / 2515 (0.00%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis toxic			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic hepatitis			
subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	2 / 2515 (0.08%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 2	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portosplenomesenteric venous thrombosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiocardiogram			

subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level above therapeutic			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood sodium decreased			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urea increased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone density abnormal			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac index abnormal			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation cardiac			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cortisol decreased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate irregular			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Occult blood positive			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Weight increased			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass occlusion			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula site complication			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asbestosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone fissure			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns third degree			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac valve replacement complication			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	0 / 2515 (0.00%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary vascular graft stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costal cartilage fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	5 / 2515 (0.20%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 5	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			

subjects affected / exposed	8 / 2515 (0.32%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Femur fracture			
subjects affected / exposed	12 / 2515 (0.48%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 12	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat illness			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	3 / 2515 (0.12%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site haemorrhage			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb crushing injury			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	5 / 2515 (0.20%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penis injury			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural hypothyroidism			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative hypotension			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			

subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sedation complication			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	0 / 2515 (0.00%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Snake bite			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			

subjects affected / exposed	1 / 2515 (0.04%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subdural haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suture related complication			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	6 / 2515 (0.24%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Traumatic fracture			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic liver injury			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic ulcer			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention postoperative			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasoplegia syndrome			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Corneal dystrophy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal arteriovenous malformation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phimosis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyloric stenosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	5 / 2515 (0.20%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	

Angina pectoris			
subjects affected / exposed	8 / 2515 (0.32%)	9 / 2519 (0.36%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	7 / 2515 (0.28%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 13	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve calcification			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	3 / 2515 (0.12%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	29 / 2515 (1.15%)	14 / 2519 (0.56%)	
occurrences causally related to treatment / all	0 / 31	0 / 15	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial flutter			

subjects affected / exposed	7 / 2515 (0.28%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial tachycardia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	3 / 2515 (0.12%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	3 / 2515 (0.12%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiac asthma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	116 / 2515 (4.61%)	82 / 2519 (3.26%)	
occurrences causally related to treatment / all	1 / 128	0 / 88	
deaths causally related to treatment / all	0 / 16	0 / 9	
Cardiac failure acute			
subjects affected / exposed	4 / 2515 (0.16%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	10 / 2515 (0.40%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	25 / 2515 (0.99%)	13 / 2519 (0.52%)	
occurrences causally related to treatment / all	0 / 25	0 / 13	
deaths causally related to treatment / all	0 / 4	0 / 1	
Cardiac perforation			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ventricular thrombosis			

subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	4 / 2515 (0.16%)	8 / 2519 (0.32%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 2	
Cardiopulmonary failure			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiorenal syndrome			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular insufficiency			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	3 / 2515 (0.12%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			

subjects affected / exposed	3 / 2515 (0.12%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve incompetence			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac thrombus			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	5 / 2515 (0.20%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	3 / 2515 (0.12%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 3	0 / 2	
Myocardial ischaemia			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			

subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular dysfunction			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	7 / 2515 (0.28%)	9 / 2519 (0.36%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			

subjects affected / exposed	27 / 2515 (1.07%)	14 / 2519 (0.56%)	
occurrences causally related to treatment / all	0 / 29	5 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic neuropathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Axonal neuropathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain hypoxia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain injury			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cauda equina syndrome			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery embolism			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral artery stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral infarction			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	6 / 2515 (0.24%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Cerebrovascular disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dementia Alzheimer's type			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	2 / 2515 (0.08%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 2	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hydrocephalus			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			

subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lethargy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myoclonus			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post stroke epilepsy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 2515 (0.00%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Spinal cord compression			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Syncope			

subjects affected / exposed	33 / 2515 (1.31%)	43 / 2519 (1.71%)	
occurrences causally related to treatment / all	2 / 35	2 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	24 / 2515 (0.95%)	41 / 2519 (1.63%)	
occurrences causally related to treatment / all	0 / 25	0 / 50	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of chronic disease			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune haemolytic anaemia			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bicytopenia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood loss anaemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone marrow failure			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocoagulable state			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 2515 (0.04%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	7 / 2515 (0.28%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Blindness			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			

subjects affected / exposed	6 / 2515 (0.24%)	9 / 2519 (0.36%)	
occurrences causally related to treatment / all	0 / 8	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular cyst			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery thrombosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	4 / 2515 (0.16%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	3 / 2515 (0.12%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal rigidity			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholic pancreatitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal ulcer			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	4 / 2515 (0.16%)	8 / 2519 (0.32%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental caries			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental cyst			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	7 / 2515 (0.28%)	10 / 2519 (0.40%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric perforation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			

subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	7 / 2515 (0.28%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	7 / 2515 (0.28%)	12 / 2519 (0.48%)	
occurrences causally related to treatment / all	0 / 7	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal toxicity			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			

subjects affected / exposed	4 / 2515 (0.16%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival bleeding			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated inguinal hernia			

subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	9 / 2515 (0.36%)	11 / 2519 (0.44%)	
occurrences causally related to treatment / all	0 / 9	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia strangulated			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia, obstructive			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal infarction			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic enteritis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal haemorrhage			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal obstruction			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer perforation			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			

subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal achalasia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatolithiasis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumatosis intestinalis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	6 / 2515 (0.24%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 6	1 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vomiting			
subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis bullous			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ecchymosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage subcutaneous			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Henoch-Schonlein purpura			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurodermatitis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	9 / 2515 (0.36%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 14	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stevens-Johnson syndrome			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Urticaria			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	51 / 2515 (2.03%)	66 / 2519 (2.62%)	
occurrences causally related to treatment / all	4 / 53	6 / 69	
deaths causally related to treatment / all	0 / 4	1 / 6	
Azotaemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bladder cyst			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder mass			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	31 / 2515 (1.23%)	40 / 2519 (1.59%)	
occurrences causally related to treatment / all	0 / 31	2 / 42	
deaths causally related to treatment / all	0 / 1	0 / 2	
Costovertebral angle tenderness			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Haematuria			
subjects affected / exposed	7 / 2515 (0.28%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 7	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephritis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	1 / 2515 (0.04%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	30 / 2515 (1.19%)	24 / 2519 (0.95%)	
occurrences causally related to treatment / all	1 / 31	1 / 25	
deaths causally related to treatment / all	0 / 0	0 / 2	
Renal impairment			
subjects affected / exposed	7 / 2515 (0.28%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal infarct			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urate nephropathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Basedow's disease			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid syndrome			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glucocorticoid deficiency			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoparathyroidism secondary			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	3 / 2515 (0.12%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondritis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enthesopathy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	6 / 2515 (0.24%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	2 / 7	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty tophus			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma muscle			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	5 / 2515 (0.20%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	4 / 2515 (0.16%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	0 / 2515 (0.00%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sjogren's syndrome			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendonitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess limb			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acinetobacter bacteraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Amoebic dysentery			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula site infection			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	7 / 2515 (0.28%)	10 / 2519 (0.40%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	19 / 2515 (0.76%)	25 / 2519 (0.99%)	
occurrences causally related to treatment / all	0 / 20	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis gangrenous			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chest wall abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complicated appendicitis			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis bacterial			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			

subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated tuberculosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 2515 (0.04%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 2	
Enteritis infectious			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterobacter bacteraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal infection			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis viral			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	6 / 2515 (0.24%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye infection bacterial			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungaemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	4 / 2515 (0.16%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gas gangrene			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	10 / 2515 (0.40%)	16 / 2519 (0.64%)	
occurrences causally related to treatment / all	0 / 10	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site cellulitis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection			
subjects affected / exposed	3 / 2515 (0.12%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected bite			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			

subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	3 / 2515 (0.12%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	3 / 2515 (0.12%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	8 / 2515 (0.32%)	11 / 2519 (0.44%)	
occurrences causally related to treatment / all	0 / 8	0 / 11	
deaths causally related to treatment / all	0 / 1	0 / 1	
Intervertebral discitis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal sepsis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	4 / 2515 (0.16%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection viral			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	3 / 2515 (0.12%)	10 / 2519 (0.40%)	
occurrences causally related to treatment / all	0 / 3	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Measles			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site abscess			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis infectious			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			

subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nosocomial infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	6 / 2515 (0.24%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteomyelitis acute			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotid abscess			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirectal abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pertussis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	116 / 2515 (4.61%)	104 / 2519 (4.13%)	
occurrences causally related to treatment / all	0 / 127	0 / 113	
deaths causally related to treatment / all	0 / 15	0 / 8	
Pneumonia bacterial			
subjects affected / exposed	4 / 2515 (0.16%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia chlamydial			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			

subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoas abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	3 / 2515 (0.12%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pyelonephritis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	4 / 2515 (0.16%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory tract infection viral			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella bacteraemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	25 / 2515 (0.99%)	16 / 2519 (0.64%)	
occurrences causally related to treatment / all	0 / 25	0 / 16	
deaths causally related to treatment / all	0 / 7	0 / 5	
Septic shock			
subjects affected / exposed	14 / 2515 (0.56%)	11 / 2519 (0.44%)	
occurrences causally related to treatment / all	0 / 14	0 / 11	
deaths causally related to treatment / all	0 / 3	0 / 5	
Serratia bacteraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin bacterial infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			

subjects affected / exposed	2 / 2515 (0.08%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal skin infection			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal bacteraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic candida			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thrombophlebitis septic			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculous pleurisy			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Typhoid fever			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	10 / 2515 (0.40%)	11 / 2519 (0.44%)	
occurrences causally related to treatment / all	0 / 10	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureter abscess			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	16 / 2515 (0.64%)	20 / 2519 (0.79%)	
occurrences causally related to treatment / all	0 / 18	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 2515 (0.00%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vestibular neuronitis			

subjects affected / exposed	2 / 2515 (0.08%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral diarrhoea			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 2515 (0.00%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
West Nile viral infection			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	4 / 2515 (0.16%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound sepsis			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			

subjects affected / exposed	12 / 2515 (0.48%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 13	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	10 / 2515 (0.40%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 11	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes with hyperosmolarity			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	2 / 2515 (0.08%)	4 / 2519 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic metabolic decompensation			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	1 / 2515 (0.04%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	12 / 2515 (0.48%)	10 / 2519 (0.40%)	
occurrences causally related to treatment / all	1 / 14	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperammonaemia			

subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 2515 (0.04%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	4 / 2515 (0.16%)	6 / 2519 (0.24%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	2 / 2515 (0.08%)	3 / 2519 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hyperkalaemia			
subjects affected / exposed	14 / 2515 (0.56%)	13 / 2519 (0.52%)	
occurrences causally related to treatment / all	0 / 14	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypernatraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperosmolar state			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoalbuminaemia			
subjects affected / exposed	2 / 2515 (0.08%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			

subjects affected / exposed	0 / 2515 (0.00%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochloraemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	9 / 2515 (0.36%)	12 / 2519 (0.48%)	
occurrences causally related to treatment / all	0 / 9	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	7 / 2515 (0.28%)	7 / 2519 (0.28%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypomagnesaemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	5 / 2515 (0.20%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophosphataemia			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			

subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Marasmus			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metabolic acidosis			
subjects affected / exposed	4 / 2515 (0.16%)	2 / 2519 (0.08%)	
occurrences causally related to treatment / all	0 / 4	1 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Metabolic alkalosis			
subjects affected / exposed	1 / 2515 (0.04%)	0 / 2519 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mineral metabolism disorder			
subjects affected / exposed	0 / 2515 (0.00%)	1 / 2519 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	8 / 2515 (0.32%)	5 / 2519 (0.20%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Vericiguat	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	925 / 2515 (36.78%)	958 / 2519 (38.03%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	331 / 2515 (13.16%)	369 / 2519 (14.65%)	
occurrences (all)	437	487	
Cardiac disorders			

Cardiac failure subjects affected / exposed occurrences (all)	157 / 2515 (6.24%) 221	160 / 2519 (6.35%) 219	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	152 / 2515 (6.04%) 169	169 / 2519 (6.71%) 195	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	134 / 2515 (5.33%) 139	165 / 2519 (6.55%) 181	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	120 / 2515 (4.77%) 136	127 / 2519 (5.04%) 141	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	132 / 2515 (5.25%) 158	127 / 2519 (5.04%) 161	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	131 / 2515 (5.21%) 163	126 / 2519 (5.00%) 153	
Metabolism and nutrition disorders Hyperkalaemia subjects affected / exposed occurrences (all)	138 / 2515 (5.49%) 167	112 / 2519 (4.45%) 124	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 June 2016	Amendment 01: The primary reason for this amendment was to update the Exclusion Criteria.
27 March 2017	Amendment 04: The primary reason for this amendment was to update the following sections of the protocol: Rationale for the Trial and Selected Patient Population; Clinical Criteria for Early Trial Termination; Statistical Analysis Plan Summary; Futility Interim Analysis; and Efficacy Interim Analysis.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported